VASOPRESSIN MARKET ANALYSIS

Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, and Subcutaneous Injection), by Application, (Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock and Ventricular Tachycardia & Fibrillation), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021
Code : CMI4646
Pages :189
Formats :
Excel and PDF
Industry : Pharmaceutical

Vasopressin MarketSize and Trends

The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).

Figure 1. Global Vasopressin Market Share (%) in Terms of Value, By Region, 2021

Figure 2. Global Vasopressin Market Share (%), by Type, 2021

The increasing regulatory approvals for vasopressin drug is expected to drive the market growth over the forecast period. For instance, in June 2021, Eagle Pharmaceuticals, Inc., announced that the U.S. Food and Drug and Administration priority review for the company’s abbreviated new drug application for its vasopressin.

The Eagle Pharmaceuticals, Inc., company’s response to the Complete Response Letter (CRL) was submitted on June 15, 2021. The U.S. FDA assigned a Generic Drug User Fee Amendments/Act GDUFA date of December 15, 2021